DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer

Interventions: Drug: cisplatin
Drug: docetaxel
Drug: gemcitabine hydrochloride
Drug: methotrexate

First Posted Date: 2003-05-16

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 6

Registration Number: NCT00005086

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: FOLFOX regimen
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2003-05-07

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT00004127

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States

and more 19 locations

Drug Treatment for Pathologic Gambling Disorder

Phase 3

Completed

Conditions: Gambling

Interventions: Drug: Placebo
Drug: Naltrexone

First Posted Date: 2003-02-05

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 83

Registration Number: NCT00053677

Locations: 🇺🇸
University of Minnesota Medical School, Minneapolis, Minnesota, United States

Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: arsenic trioxide

First Posted Date: 2003-01-28

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 13

Registration Number: NCT00053222

Locations: 🇺🇸
Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, United States
🇺🇸
LaGrange Memorial Hospital, LaGrange, Illinois, United States
🇺🇸
Ingalls Memorial Hospital, Harvey, Illinois, United States

and more 8 locations

Vaccine Therapy Plus Interleukin-12 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: PSA prostate cancer vaccine
Biological: recombinant interleukin-12

First Posted Date: 2003-01-27

Last Posted Date: 2014-03-07

Lead Sponsor: University of Chicago

Target Recruit Count: 13

Registration Number: NCT00015977

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: Cisplatin
Drug: dacarbazine
Drug: Granulocyte-macrophage colony-stimulating factor

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 46

Registration Number: NCT00004141

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Cancer

Interventions: Drug: ZD1839
Drug: oxaliplatin

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 14

Registration Number: NCT00026299

Locations: 🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States
🇺🇸
Evanston Northwestern Health Care, Evanston, Illinois, United States

and more 9 locations

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Drug/Agent Toxicity by Tissue/Organ

Interventions: Drug: amifostine trihydrate
Drug: cisplatin
Drug: gemcitabine hydrochloride
Procedure: adjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 37

Registration Number: NCT00006105

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma

Not Applicable

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 106

Registration Number: NCT00004153

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Head and Neck Cancer

Interventions: Drug: fluorouracil
Drug: hydroxyurea
Procedure: surgical procedure
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 53

Registration Number: NCT00002951

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy